Masahiro Tsuboi, MD | Authors


ADAURA Study Demonstrates Promising Efficacy for Osimertinib in EGFR-Mutant NSCLC

October 19, 2020

Masahiro Tsuboi, MD, discusses the key takeaways from the findings for osimertinib in patients with early-stage EGFR-mutant non–small cell lung cancer following a complete tumor resection in the phase 3 ADAURA clinical trial.